<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01799850</url>
  </required_header>
  <id_info>
    <org_study_id>TPNA 02-037A</org_study_id>
    <nct_id>NCT01799850</nct_id>
  </id_info>
  <brief_title>The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle</brief_title>
  <official_title>The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East Tennessee State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>East Tennessee State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with type 2 diabetes will be treated with Actos or placebo for eight weeks and
      needle biopsies of muscle will quantify changes in any of seven different glucose transport
      proteins in muscle.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twelve subjects with type 2 diabetes, with fair control on oral medication, will be recruited
      to participate in a randomized, double-blind, placebo-controlled study of the impact on
      muscle glucose transporter expression of the addition of the insulin-sensitizing agent,
      pioglitizone (Takeda Pharmaceuticals). Therapy with the active drug will be at 30 mg daily.
      The other oral medications will be adjusted downward if hypoglycemia occurs. Glycemic control
      will be monitored by at least twice daily home blood glucose monitoring, weekly telephone
      contacts, and follow-up visits to the ETSU/VAMC Clinical Research Unit (CRU) every two weeks.
      During the eight weeks of therapy, subjects will be instructed to maintain their weight and
      keep their dietary and exercise regimens unchanged. Muscle biopsies will be obtained before
      and at the end of eight weeks of therapy. Specimens will be assayed for GLUT1, GLUT3, GLUT4,
      GLUT5, GLUT8, GLUT11, and GLUT12 mRNA and protein content and the subcellular distribution of
      these proteins as described below. Peroxisome proliferator-activated receptor gamma
      (PPARgamma), a member of the ligand-activated nuclear hormone receptor superfamily (14), will
      be quantified in these specimens by immunoblot as described below.

      This study design involving a randomized, double-blinded, placebo-controlled treatment
      regimen is needed to control for confounding variables causing changes in glucose transporter
      expression that may be erroneously attributed to the drug. These potential variables include
      close contact with the diabetes management team resulting in improved compliance with diet,
      exercise, medication, and monitoring and thus better glycemic control, weight loss, or
      improved fitness.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in muscle glucose transporter expression</measure>
    <time_frame>post eight weeks treatment</time_frame>
    <description>immunoblots pre and post, placebo and Actos</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>Actos</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Actos 30 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>double blind placebo controlled</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned</description>
    <arm_group_label>Actos</arm_group_label>
    <other_name>Actos or placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo assigned randomly, double blind</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diabetes, type 2

          -  HbA1c less than 8.5

        Exclusion Criteria:

          -  insulin therapy

          -  renal insufficiency

          -  clinically apparent coronary disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles A Stuart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ETSU Quillen College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ETSU Quillen College of Medicine</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stuart CA, Howell ME, Yin D. Overexpression of GLUT5 in diabetic muscle is reversed by pioglitazone. Diabetes Care. 2007 Apr;30(4):925-31. Epub 2007 Jan 24.</citation>
    <PMID>17251278</PMID>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2013</study_first_posted>
  <last_update_submitted>February 25, 2013</last_update_submitted>
  <last_update_submitted_qc>February 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>East Tennessee State University</investigator_affiliation>
    <investigator_full_name>Charles A. Stuart</investigator_full_name>
    <investigator_title>Professor, Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>muscle</keyword>
  <keyword>glucose transporters</keyword>
  <keyword>GLUT4</keyword>
  <keyword>GLUT5</keyword>
  <keyword>Actos</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

